Aurinia Pharmaceuticals (AUPH) Proxy Filing summary

Executive summary

• LUPKYNIS® sales grew 36% to $216.2 million in 2024, with strong cash flows and zero debt at year-end.

• The company repurchased 6.1 million shares in 2024 and ended the year with $358.5 million in cash and equivalents.

• Revised treatment guidelines and a large addressable patient population support continued LUPKYNIS growth.

• Phase 1 study of pipeline candidate AUR200 began in September 2024, with results expected in Q2 2025.

Voting matters and shareholder proposals

• Shareholders will vote on electing six directors, appointing PwC as auditor, a non-binding say-on-pay, and amending the Equity Incentive Plan to add 6 million shares.

• No shareholder proposals or third-party director nominations were received for the meeting.

• Board recommends voting “FOR” all proposals and nominees.

Board of directors and corporate governance

• Board size reduced from nine to six, with four new nominees in the past year.

• 83% of nominees are independent; Chair and CEO roles are separated.

• All board committees (Audit, Compensation, Governance) are fully independent.

• Annual board and committee self-evaluations and majority voting in uncontested elections.

• No poison pill in effect; regular executive sessions of independent directors.